Indian Journal of Nuclear Medicine
Home | About IJNM | Search | Current Issue | Past Issues | Instructions | Ahead of Print | Online submissionLogin 
Indian Journal of Nuclear Medicine
  Editorial Board | Subscribe | Advertise | Contact
Users Online: 99 Print this page  Email this page Small font size Default font size Increase font size


 
 Table of Contents     
CASE REPORT
Year : 2011  |  Volume : 26  |  Issue : 3  |  Page : 163-164  

Comparison of Tc-99m MDP and Sm-153 EDTMP bone scan


1 Department of Nuclear Medicine, Cancer Institute (WIA), Adyar, Chennai, India
2 Department of Surgical Oncology, Cancer Institute (WIA), Adyar, Chennai, India

Date of Web Publication28-Nov-2012

Correspondence Address:
Krishnakumar Ramachandran
Department of Nuclear Medicine, Cancer Institute (WIA), Chennai - 600020
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0972-3919.104005

Rights and Permissions
   Abstract 

A 72-year-old male, a known case of carcinoma of prostate, had bilateral orchidectomy in 2002 and while on hormones developed multiple bone metastases in 2010. He was treated with 153 Samarium ethylene diamine tetra methylene phosphonate (EDTMP). The author compares the features of 99m Tc methylene diphosphonate (MDP) scan and 153 Sm EDTMP bone scan, highlighting the similarities of skeletal uptake.

Keywords: Carcinoma prostate, 99m Tc MDP, 153 Sm EDTMP


How to cite this article:
Ramachandran K, Kathiresan, Begum B, Rangarajan. Comparison of Tc-99m MDP and Sm-153 EDTMP bone scan. Indian J Nucl Med 2011;26:163-4

How to cite this URL:
Ramachandran K, Kathiresan, Begum B, Rangarajan. Comparison of Tc-99m MDP and Sm-153 EDTMP bone scan. Indian J Nucl Med [serial online] 2011 [cited 2019 Dec 11];26:163-4. Available from: http://www.ijnm.in/text.asp?2011/26/3/163/104005


   Introduction Top


Since mid-1930s, sodium phosphate (NaH2 32PO4), as a soluble orthophosphate, has been used for palliative treatment of multiple widespread painful metastases to bone. Advances in nuclear medicine have now added strontium chloride ( 89 Sr), Samarium [ 153 Sm ethylene diamine tetra methylene phosphonate (EDTMP)] and Rhenium hydroxyethylidene di phosphonate ( 186 Re HEDP).

153 Samarium

Samarium has a short physical half-life of 46.3 hours and is one of the shortest lived isotopes in current use for the palliation of bone pain from metastatic disease. 153 Sm decays by a beta emission and gamma photon, allowing imaging of the therapeutic isotope. The beta particle has energies of 810 keV (20%), 710 keV (50%) and 640 keV (30%) which penetrate tissue over a relatively short distance (0.83 mm of water) and a gamma energy 103 keV (29.8% abundance) is suitable for standard scintigraphic imaging. 153 Sm is complexed with EDTMP. The complex remains stable with no measurable breakdown during 48 hours. [1]


   Case Report Top


We report a case of a 72-year-old male patient with carcinoma prostrate, who had bilateral orchidectomy in 2002. In 2009, he had reactivation of bone pain and was detected to have cervical vertebral metastases. Radiation was given up to 30 Gy to the vertebrae. The patient was on hormone since then and had monthly Zolendronic acid injection i.v. (14 injections). Serum prostate specific antigen (PSA) was increased (58.8 ng/ml). In 2010, he developed diffuse body ache and 99m Tc methylene diphosphonate (MDP) scan revealed multiple uptake in axial and appendicular skeleton [Figure 1]. Radiogram of chest revealed no pulmonary metastases [Figure 2].
Figure 1: Tc 99m MDP bone scan

Click here to view
Figure 2: Chest radiograph

Click here to view


The patient was given a dose of 40 mCi of 153 Sm EDTMP intravenously. After 96 hours, whole body images were acquired (512×512 matrix) - anterior and posterior views. The scan was compared with 99m Tc MDP bone scan. Both revealed abnormal concentration in dorsolumbar vertebrae and skull, besides pelvis and ribs [Figure 3]. The metastases concentrate 153 Sm EDTMP - a prerequiirement for fixed pain relief. The patient had pain relief over a period of 1-2 weeks.
Figure 3: Sm 153 EDTMP post therapy scan

Click here to view



   Discussion Top


Eary [1] showed that the distribution of 153 Sm EDTMP was similar to that of 99m Tc MDP and had sensitivity equal to that of 99m Tc MDP bone scanning (lesion to non-lesion bone localization ranged from 2.7 to 6.7). Likewise, 153 Sm EDTMP was found to stay in the skeletal structures for approximately 42 hours and skeletal doses ranged from 20 to 32 rad/mCi with marrow doses ranging from 4.6 to 7.5 rad/mCi.

Another trial [2] also showed that lesion to normal ratios were 4.04±2.62 for 153 Sm and 4.01±1.9 for 99m Tc MDP. Likewise, ratios of lesion to soft tissue and normal bone to soft tissue were similar between the two agents and 53% of the dose was excreted by the kidneys in the first 8 hours. Clearance studies showed that 5% and 2% remained in the blood at 2 hours and at 4 hours, respectively, after injection.

Dose escalation trials [3] showed hematologic toxicity in the patients receiving higher doses and they determined a maximum tolerated dose level of 2.5 mCi/kg.

Pain relief typically occurred within 1-2 weeks after treatment, with about 12% showing a flare response after treatment. The lower dose regimen (1 mCi/kg) was compared with higher dose treatment (2.5 mCi/kg) and no definite dose-response relationship was found. [4] The duration of pain relief and survival was greater for the subgroup that received 153 Sm re-treatment than for the group that received the single-dose treatment.

153 Sm EDTMP holds great promise as a radiopharmaceutical agent for treating pain secondary to metastatic disease. With its imaging gamma photon, favorable beta energy particle, and short physical half-life, the care of patients can be optimized.

 
   References Top

1.Eary JF, Collins C, Stabin M, Vernon C, Petersdorf S, Baker M, et al. 153 Samarium EDTMP biodistribution and dosimetry estimation. J Nucl Med 1993;34:1031-6.  Back to cited text no. 1
[PUBMED]    
2.Singh A, Holmes RA, Farhangi M, Volkert WA, Williams A, Stringham LM, et al. Human Pharmacokinetics of 153 Samarium EDTMP in metastatic cancer. J Nucl Med 1989;30:1814-8.  Back to cited text no. 2
[PUBMED]    
3.Collins C, Eary JF, Donaldson G, Vernon C. 153 Samarium EDTMP in bone metastases of hormone refractory prostate carcinoma: A phase I/II trial, J Nucle Med 1993;34:1839-44.  Back to cited text no. 3
    
4.Turner JH, Martindale AA, Sorby P, Hetherington EL, Fleay RF, Hoffman RF, et al. 153 Samarium EDTMP therapy of disseminated skeletal metastasis. Eur J Nucl Med 1989;15:784-95.  Back to cited text no. 4
[PUBMED]    


    Figures

  [Figure 1], [Figure 2], [Figure 3]


This article has been cited by
1 153Sm-EDTMP for Pain Relief of Bone Metastases from Prostate and Breast Cancer and Other Malignancies
Luis Correa-González,Consuelo Arteaga de Murphy,Pablo Pichardo-Romero,Martha Pedraza-López,Claudia Moreno-García,Luis Correa-Hernández
Archives of Medical Research. 2014;
[Pubmed] | [DOI]



 

Top
  
 
  Search
 
  
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    Abstract
   Introduction
   Case Report
   Discussion
    References
    Article Figures

 Article Access Statistics
    Viewed1308    
    Printed57    
    Emailed0    
    PDF Downloaded79    
    Comments [Add]    
    Cited by others 1    

Recommend this journal